and an equivocal result in ISH may be more easily solved with a good IHC assay. This principle is indeed used in the algorithms for HER2 testing proposed by the ASCO/CAP guidelines. The ...

Pathologists supported by a new artificial intelligence tool outperformed Standard of Care/Gold standard in determining ...

The guidelines were informed by findings from the DESTINY-Breast04 trial involving 494 patients with HER2-low (defined as a score of 1+ on IHC analysis or as an IHC score of 2+ and negative ...

The agency approved the drug based on data from the DESTINY-Breast06 trial, which included patients who had tumors with very low HER2 expression.

Future Oncol. 2015;11(7):1023-1026. Tumor-negative breast cancers misclassified as HER2 negative by IHC (0 or 1+) could therefore be reclassified by FISH, with a remarkable impact on medical ...

HER2 negative breast cancer (measured as HER2 score of IHC 0, IHC 1+ or IHC 2+/ISH-).2 Endocrine therapies are widely given consecutively in the early lines of treatment for HR positive metastatic ...